GILD - Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

2024-04-18 13:59:29 ET

Summary

• Caribou Biosciences, Inc. is expected to produce results from phase 1 ANTLER study, using CB-010 for the treatment of 2nd-line large B-cell lymphoma patients, at medical meeting Q2 of 2024.
• Initial dose escalation data from the phase 1 ANTLER study indicated that CB-010 was able to generate a 90% objective response rate for patients with relapsed or refractory LBCL.
• Clearance was given by the FDA to initiate a phase 1 study using CB-010 for patients with lupus nephritis and extrarenal lupus; Trial initiation expected by the end of 2024.
• Initial dose-escalation data from the phase 1 CaMMouflage study, using CB-011 for the treatment of patients with relapsed or refractory multiple myeloma patients by end of 2024.

Caribou Biosciences, Inc. ( CRBU ) is gearing up to present initial dose expansion data from its ongoing phase 1 ANTLER study. This particular early-stage study uses CB-010 for the treatment of patients with 2nd-line relapsed or refractory large B cell lymphoma [r/r LBCL]. Positive data from the dose-escalation portion of the study was already released....

For further details see: